Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Aggressive Non-Hodgkin's Lymphoma
NCT00807495Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Feb 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), T-cell lymphoma, follicular lymphoma (FL), sponsored by Millennium Pharmaceuticals. Started Feb 2009; status: completed.
02
Drugs
alisertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Burkitt lymphoma (BL)T-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00807495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00807495.